Cargando…
Short-term outcomes of COVID-19 and risk factors for progression
With a median (IQR) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression. https://bit.ly/3crsJr0
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173674/ https://www.ncbi.nlm.nih.gov/pubmed/32312863 http://dx.doi.org/10.1183/13993003.00990-2020 |
| _version_ | 1783524500810235904 |
|---|---|
| author | Long, Li Zeng, Xiansheng Zhang, Xu Xiao, Wei Guo, E Zhan, Wenzhi Yang, Xuejiao Li, Chunyan Wu, Caiyun Xu, Tingting Zhan, Chen Chen, Yuehan Jiang, Mei Zhong, Nanshan Lai, Kefang |
| author_facet | Long, Li Zeng, Xiansheng Zhang, Xu Xiao, Wei Guo, E Zhan, Wenzhi Yang, Xuejiao Li, Chunyan Wu, Caiyun Xu, Tingting Zhan, Chen Chen, Yuehan Jiang, Mei Zhong, Nanshan Lai, Kefang |
| author_sort | Long, Li |
| collection | PubMed |
| description | With a median (IQR) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression. https://bit.ly/3crsJr0 |
| format | Online Article Text |
| id | pubmed-7173674 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-71736742020-04-21 Short-term outcomes of COVID-19 and risk factors for progression Long, Li Zeng, Xiansheng Zhang, Xu Xiao, Wei Guo, E Zhan, Wenzhi Yang, Xuejiao Li, Chunyan Wu, Caiyun Xu, Tingting Zhan, Chen Chen, Yuehan Jiang, Mei Zhong, Nanshan Lai, Kefang Eur Respir J Agora With a median (IQR) follow-up time of 24.0 (17.5–30.0) days, progression occurred in 19.6% moderate, 27.8% severe and 66.7% critical COVID-19. Neutrophil-to-lymphocyte ratio ≥2.973, age ≥50 years, male sex and comorbidity were associated with progression. https://bit.ly/3crsJr0 European Respiratory Society 2020-05-28 /pmc/articles/PMC7173674/ /pubmed/32312863 http://dx.doi.org/10.1183/13993003.00990-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
| spellingShingle | Agora Long, Li Zeng, Xiansheng Zhang, Xu Xiao, Wei Guo, E Zhan, Wenzhi Yang, Xuejiao Li, Chunyan Wu, Caiyun Xu, Tingting Zhan, Chen Chen, Yuehan Jiang, Mei Zhong, Nanshan Lai, Kefang Short-term outcomes of COVID-19 and risk factors for progression |
| title | Short-term outcomes of COVID-19 and risk factors for progression |
| title_full | Short-term outcomes of COVID-19 and risk factors for progression |
| title_fullStr | Short-term outcomes of COVID-19 and risk factors for progression |
| title_full_unstemmed | Short-term outcomes of COVID-19 and risk factors for progression |
| title_short | Short-term outcomes of COVID-19 and risk factors for progression |
| title_sort | short-term outcomes of covid-19 and risk factors for progression |
| topic | Agora |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173674/ https://www.ncbi.nlm.nih.gov/pubmed/32312863 http://dx.doi.org/10.1183/13993003.00990-2020 |
| work_keys_str_mv | AT longli shorttermoutcomesofcovid19andriskfactorsforprogression AT zengxiansheng shorttermoutcomesofcovid19andriskfactorsforprogression AT zhangxu shorttermoutcomesofcovid19andriskfactorsforprogression AT xiaowei shorttermoutcomesofcovid19andriskfactorsforprogression AT guoe shorttermoutcomesofcovid19andriskfactorsforprogression AT zhanwenzhi shorttermoutcomesofcovid19andriskfactorsforprogression AT yangxuejiao shorttermoutcomesofcovid19andriskfactorsforprogression AT lichunyan shorttermoutcomesofcovid19andriskfactorsforprogression AT wucaiyun shorttermoutcomesofcovid19andriskfactorsforprogression AT xutingting shorttermoutcomesofcovid19andriskfactorsforprogression AT zhanchen shorttermoutcomesofcovid19andriskfactorsforprogression AT chenyuehan shorttermoutcomesofcovid19andriskfactorsforprogression AT jiangmei shorttermoutcomesofcovid19andriskfactorsforprogression AT zhongnanshan shorttermoutcomesofcovid19andriskfactorsforprogression AT laikefang shorttermoutcomesofcovid19andriskfactorsforprogression |